Get started

VERTEX

VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion
Vertex’s Stock Heads for All-Time HighVertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine. The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and was set to cross the $100 billion market-capitalization threshold for the first time. The company’s experimental pain medicine VX-548 produced statistically significant, clinically meaningfully reductions in pain intensity in people with diabetic peripheral neuropathy, a type of nerve damage that can affect people with diabetes, Vertex said in a release. The pain control seen with the drug appears comparable to the “gold standard” pain medicine pregabalin, which is marketed by Viatris Inc. under the brand name Lyrica, Evercore ISI analyst Liisa Bayko wrote in a report Wednesday. Evercore analysts raised their price target on Vertex shares to $405, from $389 previously. The new data on the pain medicine “looks at least as good as or better than investor expectations,” Jefferies analysts said in a note Wednesday. Vertex is working to quickly advance the treatment to Phase 3 studies in diabetic peripheral neuropathy, Vertex’s chief medical officer, Dr. Carmen Bozic, said in a statement. Phase 3 results from a trial of the drug in acute pain are expected in the first quarter of next year. Vertex shares have gained 37% in the year to date, while the S&P 500 is up 21%. NASDAQ:VRTX is trading above the 50, 100 & 200-day Moving Averages indicating the trend might continue.
NASDAQ:VRTXLong
by DEXWireNews
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago. For me its a very good chance and low price for VRTX. strong up move with good volume crossing the negative trend crossed EMA200 and MA200 on daily chart and also on weeky chart still above EMA200 and MA200 on monthly chart still in positive trend since 2008 good position in the market good cashflow for the next years, even if products are failing
NASDAQ:VRTXLong
by JulianRichard11
1